|
1
|
No authors listed. Global surveillance and
control of hepatitis C. Report of a WHO consultation organized in
collaboration with the Viral Hepatitis Prevention Board, Antwerp,
Belgium. J Viral Hepat. 6:35–47. 1999.
|
|
2
|
Lavanchy D: The global burden of hepatitis
C. Liver Int. 29:74–81. 2009.
|
|
3
|
Persico M, Perrotta S, Persico E,
Terracciano L, Folgori A, Ruggeri L, Nicosia A, Vecchione R, Mura
VL, Masarone M and Torella R: Hepatitis C virus carriers with
persistently normal ALT levels: biological peculiarities and update
of the natural history of liver disease at 10 years. J Viral Hepat.
13:290–296. 2006.
|
|
4
|
Uto H, Kurogi J, Takahama Y, Kusumoto K,
Hayashi K, Ido A, Kohara M, Stuver SO, Moriuchi A, Hasegawa S,
Oketani M and Tsubouchi H: Alanine aminotransferase flare-up in
hepatitis C virus carriers with persistently normal alanine
aminotransferase levels in a hyperendemic area of Japan. J
Gastroenterol. 42:673–680. 2007.
|
|
5
|
Persico M, Persico E, Suozzo R, Conte S,
De Seta M, Coppola L, Palmentieri B, Sasso FC and Torella R:
Natural history of hepatitis C virus carriers with persistently
normal aminotransferase levels. Gastroenterology. 118:760–764.
2000.
|
|
6
|
Suruki R, Hayashi K, Kusumoto K, Uto H,
Ido A, Tsubouchi H and Stuver SO: Alanine aminotransferase level as
a predictor of hepatitis C virus-associated hepatocellular
carcinoma incidence in a community-based population in Japan. Int J
Cancer. 119:192–195. 2006.
|
|
7
|
Nishiguchi S, Kuroki T, Nakatani S,
Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K and
Otani S: Randomised trial of effects of interferon-alpha on
incidence of hepatocellular carcinoma in chronic active hepatitis C
with cirrhosis. Lancet. 346:1051–1055. 1995.
|
|
8
|
Ikeda K, Arase Y, Saitoh S, Kobayashi M,
Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N and Kumada H:
Interferon beta prevents recurrence of hepatocellular carcinoma
after complete resection or ablation of the primary tumor-A
prospective randomized study of hepatitis C virus-related liver
cancer. Hepatology. 32:228–232. 2000.
|
|
9
|
Arase Y, Ikeda K, Suzuki F, Suzuki Y,
Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y,
Kobayashi M and Kumada H: Interferon-induced prolonged biochemical
response reduces hepatocarcinogenesis in hepatitis C virus
infection. J Med Virol. 79:1485–1490. 2007.
|
|
10
|
Kanmura S, Uto H, Kusumoto K, Ishida Y,
Hasuike S, Nagata K, Hayashi K, Ido A, Stuver SO and Tsubouchi H:
Early diagnostic potential for hepatocellular carcinoma using the
SELDI ProteinChip system. Hepatology. 45:948–956. 2007.
|
|
11
|
Kanmura S, Uto H, Sato Y, Kumagai K,
Sasaki F, Moriuchi A, Oketani M, Ido A, Nagata K, Hayashi K, Stuver
SO and Tsubouchi H: The complement component C3a fragment is a
potential biomarker for hepatitis C virus-related hepatocellular
carcinoma. J Gastroenterol. 45:459–467. 2010.
|
|
12
|
Uto H, Kanmura S, Takami Y and Tsubouchi
H: Clinical proteomics for liver disease: a promising approach for
discovery of novel biomarkers. Proteome Sci. 8:702010.
|
|
13
|
Okanoue T, Makiyama A, Nakayama M, Sumida
Y, Mitsuyoshi H, Nakajima T, Yasui K, Minami M and Itoh Y: A
follow-up study to determine the value of liver biopsy and need for
antiviral therapy for hepatitis C virus carriers with persistently
normal serum aminotransferase. J Hepatol. 43:599–605. 2005.
|
|
14
|
Uto H, Stuver SO, Hayashi K, Kumagai K,
Sasaki F, Kanmura S, Numata M, Moriuchi A, Hasegawa S, Oketani M,
Ido A, Kusumoto K, Hasuike S, Nagata K, Kohara M and Tsubouchi H:
Increased rate of death related to presence of viremia among
hepatitis C virus antibody-positive subjects in a community-based
cohort study. Hepatology. 50:393–399. 2009.
|
|
15
|
Schirren CA, Jung MC, Gerlach JT, Worzfeld
T, Baretton G, Mamin M, Hubert Gruener N, Houghton M and Pape GR:
Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells
recognize multiple HCV epitopes and produce interferon gamma.
Hepatology. 32:597–603. 2000.
|
|
16
|
Itose I, Kanto T, Kakita N, Takebe S,
Inoue M, Higashitani K, Miyazaki M, Miyatake H, Sakakibara M,
Hiramatsu N, Takehara T, Kasahara A and Hayashi N: Enhanced ability
of regulatory T cells in chronic hepatitis C patients with
persistently normal alanine aminotransferase levels than those with
active hepatitis. J Viral Hepat. 16:844–852. 2009.
|
|
17
|
Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J,
Xiang T, Tang J, Li D, Hu Q, Ho W and Zhang X: Specifically binding
of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2
leads to complement activation. Cell Mol Immunol. 6:235–244.
2009.
|
|
18
|
Ambrus G, Gál P, Kojima M, Szilágyi K,
Balczer J, Antal J, Gráf L, Laich A, Moffatt BE, Schwaeble W, Sim
RB and Závodszky P: Natural substrates and inhibitors of
mannan-binding lectin-associated serine protease-1 and -2: a study
on recombinant catalytic fragments. J Immunol. 170:1374–1382.
2003.
|
|
19
|
Poljacki M, Gajinov Z, Ivkov M, Matić M
and Golusin Z: Skin diseases and hepatitis virus C infection. Med
Pregl. 53:141–145. 2000.
|
|
20
|
Dumestre-Perard C, Ponard D, Drouet C,
Leroy V, Zarski JP, Dutertre N and Colomb MG: Complement C4
monitoring in the follow-up of chronic hepatitis C treatment. Clin
Exp Immunol. 127:131–136. 2002.
|
|
21
|
Banerjee A, Mazumdar B, Meyer K, Di
Bisceglie AM, Ray RB and Ray R: Transcriptional repression of C4
complement by hepatitis C virus proteins. J Virol. 85:4157–4166.
2011.
|
|
22
|
Wallis R, Dodds AW, Mitchell DA, Sim RB,
Reid KB and Schwaeble WJ: Molecular interactions between MASP-2,
C4, and C2 and their activation fragments leading to complement
activation via the lectin pathway. J Biol Chem. 282:7844–7851.
2007.
|
|
23
|
Pfeifer PH, Brems JJ, Brunson M and Hugli
TE: Plasma C3a and C4a levels in liver transplant recipients: a
longitudinal study. Immunopharmacology. 46:163–174. 2000.
|
|
24
|
Avirutnan P, Fuchs A, Hauhart RE, Somnuke
P, Youn S, Diamond MS and Atkinson JP: Antagonism of the complement
component C4 by flavivirus nonstructural protein NS1. J Exp Med.
207:793–806. 2010.
|
|
25
|
Zapata R: Clinical approach to the patient
with chronic hepatitis C infection and normal aminotransferases.
Ann Hepatol. 9(suppl): 72–79. 2010.
|
|
26
|
Zeuzem S, Diago M, Gane E, Reddy KR,
Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O’Brien CB,
Lamour F and Lardelli P; PEGASYS Study NR16071 Investigator Group.
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients
with chronic hepatitis C and normal aminotransferase levels.
Gastroenterology. 127:1724–1732. 2004.
|
|
27
|
Hiramatsu N, Kurosaki M, Sakamoto N,
Iwasaki M, Sakamoto M, Suzuki Y, Sugauchi F, Tamori A, Kakinnuma S,
Matsuura K and Izumi N: Pretreatment prediction of anemia
progression by pegylated interferon alpha-2b plus ribavirin
combination therapy in chronic hepatitis C infection: decision-tree
analysis. J Gastroenterol. 46:1111–1119. 2011.
|
|
28
|
Puoti C: Hepatitis C virus with normal
transaminase levels. Dig Dis. 25:277–278. 2007.
|
|
29
|
Izumi N, Nishiguchi S, Hino K, Suzuki F,
Kumada H, Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N and
Kudo M: Management of hepatitis C: report of the consensus meeting
at the 45th annual meeting of the Japan Society of Hepatology
(2009). Hepatol Res. 40:347–368. 2010.
|
